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Abstract: Helicobacter pylori is a major human pathogen. Diagnosis of H. pylori infection and
determination of its antibiotic susceptibility still mainly rely on culture and phenotypic drug
susceptibility testing (DST) that is time-consuming and laborious. Whole genome sequencing (WGS)
has recently emerged in medical microbiology as a diagnostic tool for reliable drug resistance prediction
in bacterial pathogens. The aim of this study was to compare phenotypic DST results with the
predictions based on the presence of genetic determinants identified in the H. pylori genome using WGS.
Phenotypic resistance to clarithromycin, metronidazole, tetracycline, levofloxacin, and rifampicin was
determined in 140 clinical H. pylori isolates by E-Test®, and the occurrence of certain single nucleotide
polymorphisms (SNPs) in target genes was determined by WGS. Overall, there was a high congruence
of >99% between phenotypic DST results for clarithromycin, levofloxacin, and rifampicin and SNPs
identified in the 23S rRNA, gyrA, and rpoB gene. However, it was not possible to infer a resistance
phenotype for metronidazole based on the occurrence of distinct SNPs in frxA and rdxA. All 140
H. pylori isolates analysed in this study were susceptible to tetracycline, which was in accordance with
the absence of double or triple nucleotide substitutions in the 16S rRNA gene.
Keywords: Helicobacter pylori; whole genome sequencing; antibiotic resistance prediction; phenotypic
drug susceptibility testing; laboratory automation
1. Introduction
Helicobacter pylori is a gram-negative bacterium that infects about half of the world’s human
population. Unless treated, colonization in the human gastrointestinal tract persists lifelong. H. pylori
infection represents a key factor in the aetiology of various gastroduodenal diseases, including chronic
active gastritis, peptic or duodenal ulcers, gastric adenocarcinoma, and mucosa associated tissue
lymphoma [1–3]. The current first-choice empiric regimen for H. pylori eradication in countries
with clarithromycin resistance <15% consists of a clarithromycin-based triple therapy with a proton
pump inhibitor (PPI) in combination with metronidazole or amoxicillin [4,5]. However, in the last
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years, the effectiveness of this empiric first-line therapy has been steadily reduced due to increasing
clarithromycin and/or metronidazole resistance in H. pylori [6–8]. Alternatively, non-bismuth or
bismuth containing quadruple therapy combined with tetracycline, levofloxacin, or rifabutin-based
antibiotic regimens can be administered to patients [5,9]. However, the increase in quinolone
resistant H. pylori strains [10,11], and the emergence of quadruple-resistant H. pylori clinical isolates
in Western Europe [8,12] emphasize the need for more rapid and cost effective molecular methods
that enable reliable prediction of antibiotic resistance phenotypes prior to the administration of
antimicrobial therapy.
Diagnosis of H. pylori infection and determination of the pathogen’s antibiotic susceptibility
mainly relies on bacterial culture and phenotypic drug susceptibility testing (DST), typically delivering
results within two weeks. However, visual inspection of minimum inhibitory concentrations (MICs)
on the E-Test® strips leaves great scope for personal interpretation and potentially leads to high
inter-observer variability due to the fastidious growth of H. pylori [13].
Recently, whole-genome sequencing (WGS) from cultured bacterial isolates has emerged as
an important tool for surveillance and antibiotic resistance control. This primarily owes to improvements
in sequencing technologies, affordable instrument pricing, user friendly and simple workflows requiring
little hands on time, availability of standardized protocols and reagents, and reasonable per sample
costs (150 EUR per 5 MB genome in the case of the Illumina MiSeq), and are hence an attractive choice
as a diagnostic tool to detect drug resistance in diagnostic microbiology laboratories. Within a clinically
relevant timeframe (24 to 48 h), WGS provides a comprehensive view of the genotype of a bacterial
isolate [14,15]. In principle, the genome sequence contains all the information required to determine
the antibiotic resistance phenotype. The biggest challenge, however, lies in the identification of
high-confidence single nucleotide polymorphisms (SNPs) associated with resistance against a certain
drug. Genotype-based prediction of phenotypic resistance is less complex for H. pylori than for other
bacteria as antibiotic resistance is primarily based on point mutations in the genome and resistance
determinants in H. pylori seem not to be encoded on plasmids, transposons, or integrons [16].
In detail, clarithromycin resistance in H. pylori has been associated with point mutations in domain
V of the 23S rRNA gene, namely at the nucleotide position, A2146 and A2147 (positions according to
H. pylori reference strain 26695; correspond to nucleotides A2058 and A2059 in Escherichia coli) [17].
Some studies have reported point mutations outside these positions, but their association with
clarithromycin resistance is still a matter of debate [18–20]. Amino acid (aa) exchanges in the
quinolone resistance-determining region (QRDR) of the H. pylori gyrA gene at codons 87 and
91 (positions according to H. pylori reference strain 26695; corresponds to codons 83 and 87 in
Escherichia coli) alone or in combination with mutations in gyrB have been reported to lead to resistance
to fluoroquinolones [10,11,21]. Rifampicin resistance in H. pylori has been associated with aa exchanges
in the rifampicin resistance-determining region (RRDR) of rpoB, mainly at codons 525 to 545, 547,
and 586 (positions according to H. pylori reference strain 26695; corresponds to codons 512 to 573 in
Escherichia coli) [22]. The mechanism of resistance to metronidazole is less clear. Frameshift mutations
and truncations in genes that encode electron transfer proteins, such as the nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH)-flavin nitroreductase (frxA) and oxygen-insensitive
NADPH nitroreductase (rdxA), have been implicated in elevated MIC values to metronidazole [23,24].
Thus far, it is unclear, whether elevated metronidazole MIC values lead to therapeutic failure [25].
For tetracycline, one resistance mechanism appears to be single, double, or triple base pair substitutions
in the primary binding site of tetracycline (at nucleotide positions 926 to 928) in the 16S rRNA gene [26].
Here, we report on the first sequencing study that systematically applied WGS to H. pylori clinical
isolates to detect specific point mutations in the 23S rRNA, gyrA, rpoB, frxA, rdxA, and 16S rRNA genes.
We aimed at correlating the occurrence of SNPs in these target genes to phenotypic DST results for
each drug investigated, thereby allowing the calculation of predictive sensitivities and specificities of
each set of SNPs.
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2. Materials and Methods
2.1. Clinical H. pylori Isolates and H. pylori Culture
This study was conducted using a set of 140 H. pylori strains from the bacterial strain collection of
the Institute of Medical Microbiology (IMM), University of Zurich. The H. pylori strains were isolated
between 2013 and 2017 from gastric biopsy specimens that were sent to the IMM for culture-based
phenotypic DST. For this study, H. pylori strains were intentionally selected based on their antimicrobial
resistance phenotype and are therefore not representative of H. pylori primary antibiotic resistance
epidemiology in Switzerland. After thawing, the strains were incubated on in-house produced Brucella
agar plates (with 5% horse blood) for 3 days at 37 ◦C under microaerobic conditions (90% N2, 5% CO2,
5% O2) using a gas generator (CampyGen, Thermo Scientific, Waltham, MA, USA). After 3 days,
H. pylori isolates were subcultured on Brucella agar plates to obtain sufficient biomass for the E-Test®
(bioMérieux, Marcy l’Etoile, France) and to perform DNA extraction for WGS.
2.2. Phenotypic DST by E-Test®
H. pylori cultures were adjusted to a McFarland standard of 3 [27]. Phenotypic DST was
performed on Mueller Hinton agar plates containing 5% horse blood (bioMérieux), using the
following E-Tests® (bioMérieux): Clarithromycin (0.016–256 mg/L), metronidazole (0.016–256 mg/L),
levofloxacin (0.016–32 mg/L), rifampicin (0.016–32 mg/L), and tetracycline (0.016–32 mg/L). Agar plates
were incubated under microaerobic conditions at 37 ◦C for 3 days. Subsequently, MICs were
determined using a light microscope (Leica M80, Leica Microsystems, Heerbrugg, Switzerland).
Susceptibility interpretation was performed according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [28], except for rifampicin, for which the susceptibility interpretation
(MIC: S ≤ 4; R > 4) was done according to Hays et al. [22] and the Comité de l’Antibiogramme de la
Société Française de Microbiologie (CASFM)/EUCAST recommendations for H. pylori [29] (Figure 1).
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Figure 1. Antimicrobial drug susceptibility determined by E-Test® in 140 clinical H. pylori isolates
selected from the bacterial strain collection of the Institute of Medical Microbiology, University of
Zurich, Switzerland. Clinical breakpoints issued by EUCAST [28] are displayed for all five drugs (black
dashed line). For rifampicin, the clinical breakpoint of 4 mg/L [22,29] is displayed as a red dashed line;
R denotes resistant and S denotes susceptible.
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2.3. DNA Extraction, Library Preparation, and WGS of H. pylori Strains
DNA extraction from H. pylori cultures was performed with the DNeasy® UltraClean® Microbial
kit (Qiagen, Hilden, Germany), following the producers’ recommendations. Library preparation
was done using the Qiagen® QIAseq FX DNA kit (Qiagen, Hilden, Germany), according to the
producers’ recommendations. Sequencing library quality and size distribution were analysed on
a fragment analyser automated CE system (Advanced Analytical Technologies Inc., Heidelberg,
Germany), according to the manufacturers’ instructions using the fragment analyser 474 HS next
generation sequencing (NGS) kit. Sequencing libraries were pooled in equimolar concentrations and
paired-end sequenced (2 × 150 bp) on an Illumina MiSeq platform (Illumina®, San Diego, CA, USA).
2.4. Bioinformatic Analysis
Raw sequencing reads (fastq) were filtered and trimmed using the FASTQ trimmer tool of the
FASTX-Toolkit (Hannon Lab, Cold Spring Harbour Laboratories, Cold Spring Harbor, NY, USA)
applying a threshold PHRED score of 25. To identify SNPs in genes conferring resistance, fastq files
were analysed using the ARIBA pipeline [30], querying a custom-made database of gene sequences
derived from the H. pylori reference strain 26695 (NCBI reference sequence: NC_000915.1). For the
evaluation of metronidazole resistance, all SNPs in rdxA, frxA, mdaB, omp11, and rpsU that occurred
more frequently in metronidazole resistant than susceptible H. pylori isolates were assessed.
In order to identify probable plasmid-encoded resistance genes, trimmed and filtered
FASTQ sequencing files were analysed using the plasmidSPAdes pipeline (Version 3.10.1; [31]).
Obtained contigs were used to perform a blastn search querying the NCBI Nucleotide database.
2.5. Discrepancy Analysis
H. pylori isolates showing discrepant phenotypic DST and WGS results were sent to the French
National Reference Centre for Campylobacter and Helicobacter (Bordeaux, France) (www.cnrch.fr) for
repetition of phenotypic DST. Briefly, H. pylori isolates were adjusted to a McFarland of 3 and grown
on in-house produced Mueller Hinton agar plates (with 10% sheep blood and globular extract) for
48 h at 35 ◦C in a microaerobic atmosphere (5% O2, 10% CO2, and 85% N2) in a special workstation
(Baker, Ruskin, Concept, Bridget, UK). After 48 h, MICs were determined by E-Test® (bioMérieux),
and antibiotic susceptibilities were assessed based on the CASFM/EUCAST recommendations for
H. pylori [29].
In addition, all discrepant H. pylori strains were grown on in-house produced Brucella agar
plates (with 5% horse blood), and DNA extraction for WGS was repeated at the Institute of Medical
Microbiology, Zurich, Switzerland.
2.6. Statistics and Data Analysis
We used the 2× 2 contingency table to calculate the agreement between WGS and phenotypic DST
results [32,33]. In this context, specificity describes the likelihood that SNPs identified in a target gene
lead to phenotypic drug resistance, while sensitivity describes the proportion of resistant cases that
are identified through that set of SNPs. A major error occurred if a H. pylori strain that was identified
as susceptible by phenotypic DST was determined resistant by WGS. In this case, an alternative
antimicrobial regimen would have been prescribed to the patient, though first line treatment could
be administered. A very major error occurred if an H. pylori strain that was identified as resistant
by phenotypic DST was determined susceptible by WGS. In this case, the organism would be falsely
assessed as susceptible, resulting in the administration of an ineffective first-line antibiotic therapy.
A chi-square test (X2) of independence was performed to examine the relationship between the
occurrence of certain SNPs and the antibiotic resistance phenotype. All statistics and data visualization
was done in R [34].
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2.7. Declarations
2.7.1. Ethics Approval and Consent to Participate
The study was conducted according to good laboratory practice and in accordance with the
Declaration of Helsinki and national and institutional standards. The Swiss act on medical research
involving human subjects does not apply to this study as solely bacterial strains and no human
health-related data were used in this study.
2.7.2. Consent for Publication
No consent for publication is required. The Swiss act on medical research involving human
subjects do not apply to this study as solely bacterial strains and no human health-related data
were used.
3. Results
3.1. Occurrence of Plasmids Carrying Resistance Genes in H. pylori
In the 140 analysed H. pylori genomes, we did not detect a single plasmid encoding a resistance
gene. This points towards the primary importance of SNPs in target genes in mediating phenotypic
drug resistance in H. pylori and facilitates the prediction of resistance phenotypes.
3.2. Coherence in Prediction of Clarithromycin Resistance
Forty-three H. pylori strains showed a clarithromycin susceptible phenotype and, accordingly,
displayed no mutations in domain V of the 23S rRNA gene at nucleotide position A2146 or A2147.
Two of the 43 susceptible H. pylori isolates (with MICs of 0.016 and 0.023 mg/L) carried a G2224A
mutation, which does not cause macrolide resistance [35].
One isolate carried a T2182C mutation and exhibited a low-level clarithromycin resistance
with an MIC of 1.5 mg/L. As the relevance of the T2182C mutation in clarithromycin resistance
is questionable [18], this strain was sent for retesting to the H. pylori reference centre in Bordeaux,
where an MIC of 0.5 mg/L was determined (Table S1). Thus, initially, phenotypic DST falsely identified
this H. pylori strain as clarithromycin resistant, representing a major error.
Two H. pylori strains initially showed an MIC of 0.19 and 0.5, but carried an A2146G and
an A2147G mutation, respectively. Repetition of the E-Test® eventually revealed a mixed population of
clarithromycin susceptible and resistant H. pylori strains (0.19 and 6; 0.5 and >256). These two samples
were scored as clarithromycin resistant H. pylori strains for further statistical analysis (Tables 1 and 2).
Table 1. Point mutations identified by WGS in the 23S rRNA gene at nucleotide positions, A2146 and
A2147, in 96 clarithromycin resistant H. pylori isolates and their corresponding MICs.
Number of Clinical H. pylori Strains MIC of Clarithromycin (mg/L) 23S rRNA Mutation a
1 >256 A2146C
28 8 to 256 A2146G
67 1.5 to 256 A2147G
a Nucleotide exchange relative to H. pylori reference strain 26695 sequence. WGS: whole genome sequencing MICs:
minimum inhibitory concentrations.
Thus, in total, 96 H. pylori isolates were determined as clarithromycin resistant by phenotypic DST,
and 28 A2146G (29%), 67 A2147G (70%), and one A2146C (1%) mutation were found (Tables 1 and 2).
Moreover, different point mutations resulted in different levels of clarithromycin resistance. While A2147G
isolates showed MICs of 1.5 to >256, strains harbouring either the A2146G or the A2142C point mutation
always displayed high clarithromycin resistance levels (MIC of 8 to ≥256 mg/L) (Table 1, Figure S1
Panel A).
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Table 2. Agreement between phenotypic DST results and identified point mutations in the 23S rRNA
gene at nucleotide positions, A2146 and A2147, conferring resistance to macrolides (N = 140).
Phenotypic DST
Susceptible Resistant
WGS
Susceptible a 43 1
Resistant b 0 96
a no mutation present at nucleotide positions, A2146 and A2147, in the 23S rRNA gene. b A mutation present at
nucleotide positions, A2146 and A2147, in the 23S rRNA gene. DST: drug susceptibility testing.
Overall, the congruence between the phenotypic DST and WGS results was 99%.
Specificity, i.e., the likelihood that the presence of a mutation at nucleotide position A2146 and
A2147 in the 23S rRNA gene resulted in a clarithromycin resistant phenotype, was 100%. Sensitivity,
which describes the proportion of resistant isolates that were identified through the presence of
a mutation at nucleotide positions, A2146 and A2147, was also 100%. Thus, the presence of point
mutations, A2146C, A2146G, and A2147G, in the 23S rRNA gene of H. pylori could be significantly
related to phenotypic clarithromycin resistance (X2 [1, N = 140] = 135.4, p < 0.001).
3.3. Coherence in Prediction of Metronidazole Resistance
Frameshift mutations and truncations in the genes, rdxA or frxA, are generally supposed to lead
to metronidazole resistance in H. pylori [24]. Some frameshift mutations (occurring at codon positions,
105, 149, or 192, in frxA and 18, 38, and 112 in rdxA) were only detected in metronidazole resistant
H. pylori isolates (Tables S2 and S3). Other frameshift mutations (occurring at codon positions 18 in
frxA and 62, 96, and 162 in rdxA) occurred in both metronidazole susceptible and resistant H. pylori
strains (Tables S2 and S3). SNPs resulting in the aa exchanges, A67V, A68E, K64N, P106S, and R16C,
merely occurred in the rdxA gene of metronidazole resistant H. pylori strains (Table S4). All frameshift
mutations and aa exchanges detected in rdxA and frxA of the H. pylori isolates and their corresponding
metronidazole MIC are displayed in Tables S5 and S6. Interestingly, we did not detect any published
SNPs associated with phenotypic metronidazole resistance within mdaB, omp11, or rpsU that were
more prevalent in metronidazole resistant compared to susceptible H. pylori isolates.
3.4. Coherence in Prediction of Levofloxacin Resistance
In 90 of the 91 levofloxacin susceptible H. pylori isolates, the gyrA QRDR carried no SNP at codon
87 or 91. One H. pylori strain harboured an N87T aa exchange that has not been associated with
levofloxacin resistance [11]. In 46 fluoroquinolone resistant H. pylori strains, WGS identified SNPs at
codon 87 (N = 25; 54%), codon 91 (N = 19, 41%), and at codon 87 and 91 (N = 2; 5%) (Tables 3 and 4).
Single aa exchanges at codon 87 or 91 led to a relatively broad range of levofloxacin MICs (4 to 32 mg/L).
High-level resistance (i.e., MIC > 32 mg/L) was exclusively found in the presence of aa exchanges at
codons 87 and 91 (Table 3).
Table 3. Amino acid exchanges identified by WGS in the QRDR of the gyrA gene at codon 87 and/or
91 in 46 levofloxacin resistant H. pylori isolates and their corresponding MICs.
Number of Clinical H. pylori Strains MIC of Levofloxacin (mg/L) gyrA aa Exchange a
1 >32 N87I
22 >32 N87K
2 4 to 32 N87Y
8 16 to 32 D91G
5 4 to 32 D91N
6 4 to 32 D91Y
2 >32 N87K D91N
a Amino acid exchange relative to H. pylori reference strain 26,695 sequence. QRDR: Quinolone resistance
determinig region.
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Table 4. Agreement between phenotypic DST results and identified aa exchanges in the gyrA gene at
codon 87 and/or 91 conferring resistance to fluoroquinolones (N = 138).
Phenotypic DST
Susceptible Resistant
WGS
Susceptible a 91 1
Resistant b 0 46
a no aa exchange present in the QRDR of the gyrA gene at codon 87 and/or 91. b An aa exchange present in the
QRDR of the gyrA gene at codon 87 and/or 91.
Three strains were phenotypically resistant to levofloxacin with MICs of 2 and 4 mg/L,
respectively, but showed no SNPs in the gyrA QRDR (Figure S1, Panel B). Unfortunately, two of the
three H. pylori strains showing discrepant results could not be regrown for discrepancy analysis. Thus,
we were not able to verify the correctness of phenotypic DST or WGS and decided to subsequently
exclude these two H. pylori strains from the study. The third H. pylori strain could be regrown and was
sent for retesting to the H. pylori reference centre in Bordeaux. There, it showed an MIC of 1.5 mg/L
(Table S1). The gyrB gene of this discrepant H. pylori isolate was analysed as well and showed multiple
unpublished SNPs (compared to the gyrB sequence of the H. pylori reference strain 26695; Table S7).
The congruence between the phenotypic DST and WGS results was 99%. Specificity, i.e.,
the likelihood that aa exchanges in the QRDR of the gyrA gene at codon 87 and 91 confer levofloxacin
resistance, was 100%. Sensitivity, i.e., the proportion of resistant cases that were identified through the
presence of specific aa exchanges at codon 87 and 91 in the gyrA gene, was 98%. Overall, one major
error occurred: One H. pylori isolate tested levofloxacin resistant by phenotypic DST was categorized as
susceptible by WGS. Nevertheless, specific aa exchanges at codon 87 (N87I, N87K and N87Y) and 91
(D91N and D91Y) of the gyrA gene in H. pylori can be used to predict phenotypic levofloxacin resistance
(X2 [1, N = 138] = 136.0, p < 0.001).
3.5. Coherence in Prediction of Rifampicin Resistance
All 136 rifampicin susceptible H. pylori isolates (MIC ≤ 4 mg/L) did not show an aa exchange in
the RRDR of the rpoB gene. The four phenotypic resistant H. pylori isolates with MICs >32 mg/L had
either an H540N (N = 2) or an L525P (N = 2) aa exchange (Tables 5 and 6). Overall, an agreement of
100% was found between the WGS and phenotypic rifampicin susceptibility results.
Table 5. Amino acid exchanges identified by WGS in the RRDR of the rpoB gene conferring resistance
to rifamycins and their corresponding MICs.
Number of Clinical H. pylori Strains MIC of Levofloxacin (mg/L) rpoB aa Exchange a
2 >32 H540N
2 >32 L525P
a Amino acid exchange relative to H. pylori reference strain 26,695 sequence.
Table 6. Agreement between phenotypic DST results and identified aa exchanges in the RRDR of the
rpoB gene conferring resistance to rifamycins (N = 140).
Phenotypic DST
Susceptible Resistant
WGS
Susceptible a 136 0
Resistant b 0 4
a No aa exchange present in the RRDR of the rpoB gene. b An aa exchange present in the RRDR of the rpoB gene.
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3.6. Coherence in Prediction of Tetracycline Resistance
All 140 H. pylori strains included in this study were tetracycline susceptible in phenotypic DST.
In two isolates with MICs of 0.25 and 0.5 mg/L, an A926T mutation was detected in the 16S rRNA
gene. One H. pylori isolate showed an A926G mutation with an MIC of 0.032 mg/L, and one carried
an A928C mutation with an MIC of 0.125 mg/L (Table 7). It has been previously reported that
an A926G or an A928C nucleotide exchange was associated with a broad range of MICs, ranging from
susceptible (0.75 mg/L) to low level resistance (4 mg/L), whereas double mutants displayed MICs of
>4 mg/L [36,37].
Table 7. Point mutations identified by WGS in the primary binding site of tetracycline in the 16S rRNA
gene at nucleotide positions, 926 to 928, and their corresponding MICs.
Number of Clinical H. pylori Strains MIC of Levofloxacin (mg/L) 16S rRNA Mutation a
2 0.25 to 0.5 A926T
1 0.032 A926G
1 0.125 A928C
a Nucleotide exchange relative to H. pylori reference strain 26,695 sequence.
4. Discussion
In the present study, we have applied massive parallel Illumina-based WGS on clinical H. pylori
isolates to define the relationship between the occurrence of SNPs in selected target genes and
phenotypic antimicrobial susceptibility. We could show a clear correlation between the occurrence of
point mutations in the 23S rRNA, gyrA, and rpoB genes of H. pylori and macrolide, fluoroquinolone,
and rifamycin resistance, respectively. To our knowledge, this is the first study showing that genetic
determinants of antimicrobial resistance identified by WGS can be used for the prediction of drug
resistance phenotypes in H. pylori. In contrast, there was no clear association between identified SNPs
in frxA and rdxA and phenotypic metronidazole resistance.
During this study, we realized that assessment of antimicrobial susceptibility in H. pylori by culture
based phenotypic DST can be challenging due to the pathogen’s fastidious growth requirements.
Moreover, it was not always possible to determine an explicit MIC of a drug by E-Test® because of the
small and transparent colonies that H. pylori forms. Variations in the redox potential of the test medium
caused a broad range of MIC distributions, especially for metronidazole, when performing the E-Test®,
thereby making standardized and reproducible interpretation difficult. Phenotypic DST may also be
challenged when a mixed population of resistant and susceptible H. pylori strains is present in the
same patient [38]. In two samples included in this study, phenotypic DST initially did not detect the
resistant sub-population. This is problematic, as antimicrobial therapy is based on in vitro phenotypic
susceptibly information. In contrast, the presence of susceptible and resistant H. pylori subpopulations
can be predicted from the WGS sequencing data through the occurrence of hetero-resistance at specific
nucleotide positions [38].
Molecular based methods, like polymerase chain reaction (PCR) and line probe assays, that enable
specific detection of point mutations in the 23S rRNA (nucleotide positions, A2146 and A2147) or gyrA
gene (codons 87 and 91) can be directly applied on clinical specimens [39,40]. Our data indicate that
molecular assays targeting these point mutations would be sufficient to monitor clarithromycin and
levofloxacin resistance in H. pylori. However, one advantage of WGS is that it delivers a more complete
picture of resistance determinants present in a clinical isolate than targeted molecular approaches that
can only examine a limited number of nucleotide positions. Thus, false negative results may occur,
when new polymorphisms, potentially conferring drug resistance, arise that are not covered by the
assay. In contrast, the relevance of these polymorphisms can easily be assessed by retrospective analysis
of WGS data, whereas targeted molecular assays would need to be redesigned and samples retested.
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In this study, we found clarithromycin resistance in H. pylori to be highly correlated with the
presence of mutations A2146C, A2146G or A2147G in the domain V of the 23S rRNA gene. Recent studies
reported additional point mutations outside the domain V and an active drug efflux mechanism to be
involved in clarithromycin resistance [35,41]. Also, mutations in other target genes, like rpl22 (encodes
a ribosomal protein that interacts with the 23S rRNA domains) and infB (encodes translation initiation
factor, IF-2), were identified to induce low level clarithromycin resistance (MICs of 0.5 to 4 mg/L).
Interestingly, these mutations led to a high level of clarithromycin resistance (MICs >256 mg/L) in
combination with A2146 and A2147 mutations [42]. In a recent study, it was reported that mutations
in multidrug efflux transporter genes may be involved in clarithromycin resistance [43]. In this study,
however, we found that the occurrence of point mutations at nucleotide positions, A2146 and A2147,
were sufficient for the reliable prediction of phenotypic clarithromycin resistance in H. pylori.
For metronidazole, there was no clear correlation between the isolates’ observed phenotype
and their genotype. Firstly, frameshift mutations in rdxA and frxA that were reported to confer
metronidazole resistance were also found in H. pylori strains assessed as metronidazole susceptible
by phenotypic DST. Secondly, in contrast to recent reports suggesting that metronidazole resistance
requires mutations in both genes, frxA and rdxA, one isolate was found to be resistant (MIC of 26 mg/L)
though carrying only a mutation in frxA [44,45]. Some rdxA and frxA mutations were identified in
metronidazole resistant H. pylori isolates; however, several metronidazole resistant strains harboured
no mutations at all in rdxA and/or frxA. Recently, it has been reported that additional genes, such as
mdaB, omp11, and rpsU, may be involved in metronidazole resistance in H. pylori [46,47]. However,
consensual data are still lacking and a relationship between SNPs detected in one of these five genes
(rdxA, frxA, mdaB, omp11, and rpsU) and phenotypic metronidazole resistance was not found in the
H. pylori isolates investigated in this study. In sum, it remains difficult to predict metronidazole
susceptibility based merely on genotypic data, as the correlation between detected SNPs and the
phenotype to date is very poor.
On the basis of the presented data, we therefore suggest to reconsider the usefulness of phenotypic
metronidazole susceptibility testing in H. pylori as it is stated in the CASFM/EUCAST recommendations
for H. pylori [29]. Moreover, in vitro and in vivo resistance data are not congruent [48] as H. pylori strains
tested resistant in vitro can still be eradicated with a combination therapy that contains an increased
dosage of metronidazole [25].
Resistance to fluoroquinolones could be attributed to mutations in the QRDR of gyrA at codons
87 and 91 in 98% of the fluoroquinolone resistant H. pylori strains. One levofloxacin resistant H. pylori
strain with an MIC of 1.5 mg/L showed no codon exchange in the QRDR of gyrA. The relevance
of mutations in other target genes, like gyrB, in quinolone resistant H. pylori isolates without gyrA
mutations is not consensual [49,50]. The aforementioned isolate harboured various SNPs in gyrB;
however, none matched any mutations recently reported to be associated with quinolone resistance in
H. pylori [49,51]. Notably, H. pylori lacks genes encoding topoisomerase IV (encoded by parC and parE
genes), which is targeted by quinolones in other bacteria [52]. Moreover, active efflux pumps seem not
to be involved in mediating fluoroquinolone resistance [53].
In our study, H. pylori strains with a rifampicin susceptible phenotype (i.e., MICs≤ 4 mg/L) showed
no mutation in the RRDR of rpoB. Amino acid substitutions, L525P and H540N, were associated with
resistance and MICs of >32 mg/L. Noteworthy, application of the current EUCAST clinical breakpoint
for rifampicin of 1 mg/L would split the wild-type population (Figure 1). This in turn introduces serious
interpretation problems, since some H. pylori strains that do not carry point mutations in the RRDR of
rpoB would be classified as rifampicin resistant, representing a major error. Given the rifampicin MIC
distribution of H. pylori isolates analysed in this study, we recommend using the clinical breakpoint of
4 mg/L proposed by Hays et al. [22] and the CASFM/EUCAST guidelines [29].
Findings gained in this study can be useful for future research that may aim at performing
culture-independent WGS directly from clinical specimens for the prediction of phenotypic drug
susceptibility in H. pylori. Some studies have already successfully applied WGS directly on gastric
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biopsies for the detection of H. pylori [54,55]. Moreover, in-house developed and commercial protocols
(e.g., [56,57]) are becoming available for the depletion of human DNA or the enrichment of bacterial
DNA prior to performing WGS, thereby increasing the efficiency and cost-effectiveness of NGS due to
less human DNA background in samples.
Our study has several limitations: It was designed as a single centre laboratory-based study
using clinical H. pylori isolates. For some antibiotics, there were only a few (i.e., rifampicin) or no
resistant H. pylori isolates (i.e., tetracycline) available. Thus, the analytical sensitivity of WGS in
determining phenotypic rifampicin resistance based on mutations in the RRDR of rpoB might have
been overestimated as rifampicin resistance has also been reported in H. pylori isolates lacking these
mutations [8]. For tetracycline, calculation of the analytical sensitivity of WGS was not possible due to
a lack of resistant H. pylori isolates. Moreover, genotype-based prediction of tetracycline resistance
in H. pylori is additionally hampered since isolates without mutations at nucleotide positions, 926 to
928, in the 16S rRNA gene display a resistant phenotype [58]. Therefore, tetracycline resistance seems
to be multifactorial, involving alterations in ribosomal binding, enzymatic degradation of antibiotics,
a reduction of membrane permeability, and an active efflux [59–61].
In this study, we have not examined the possible role of active efflux mechanisms. Their involvement
in intrinsic antibiotic resistance in H. pylori is still a matter of debate and would require transcriptional
analyses of the genes encoding drug efflux systems (e.g., by using a meta-transcriptomics approach),
which was beyond the scope of this study.
5. Conclusions
It is evident that increasing antimicrobial resistance represents a significant challenge in the
successful management of H. pylori infections. This highlights the importance of rapid determination
of drug susceptibility in tailoring treatments to increase H. pylori eradication success. In addition
to culture based phenotypic DST, high-throughput sequencing is rapidly changing the landscape in
medical microbiology. In this study, we could demonstrate that genetic determinants identified by
WGS in the H. pylori genome are significantly correlated to phenotypic drug resistance. This allows the
prediction of phenotypic clarithromycin, rifamycin, and levofloxacin resistance based on genotypic
information in the 23S rRNA, gyrA, and rpoB genes with high specificity and good sensitivity in
a clinically relevant timeframe.
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